CytomX Therapeutics, Inc. To Present Overview Of Precision Cancer Immunotherapies At The Jefferies Immuno-Oncology Summit
SOUTH SAN FRANCISCO, April 13, 2015 /PRNewswire/ -- CytomX, a biotechnology company developing Probody therapeutics for the treatment of cancer, today announced that Sean McCarthy, D. Phil., chief executive officer, will present at the upcoming Jefferies Immuno-Oncology Summit in Boston at 12:20 p.m. EDT on Wednesday, April 15. Dr. McCarthy will provide an overview of CytomX's Probody pipeline, including the company's precision cancer immunotherapy programs.
About CytomX Therapeutics
CytomX Therapeutics develops Probody therapeutics for the treatment of cancer. Probodies are masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology. CytomX has attracted multiple strategic collaborations with industry-leading pharmaceutical companies including Pfizer Inc., ImmunoGen and Bristol-Myers Squibb. CytomX is led by a seasoned and proven management team and is financed by leading life science investors, including Third Rock Ventures, Canaan Partners, Roche Venture Fund and Pfizer Venture Investments. For more information, please visit www.cytomx.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cytomx-to-present-overview-of-precision-cancer-immunotherapies-at-the-jefferies-immuno-oncology-summit-300064513.html
SOURCE CytomX Therapeutics